Hsa-miR-375 is a Predictor of Local Control in Early Stage Breast Cancer

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2016 Mar 11

PMID 26962366

Citations 25

Authors

Franz Zehentmayr

Cornelia Hauser-Kronberger

Barbara Zellinger

Falk Hlubek

Claudia Schuster

Ulrich Bodenhofer

Gerd Fastner

Heinz Deutschmann

Philipp Steininger

Roland Reitsamer

Thorsten Fischer

Felix Sedlmayer

Affiliations

Soon will be listed here.

Abstract

Background: A long-term analysis by the Early Breast Cancer Trialist Group (EBCTG) revealed a strong correlation between local control and cancer-specific mortality. MicroRNAs (miRs), short (20-25 nucleotides) non-coding RNAs, have been described as prognosticators and predictors for breast cancer in recent years. The aim of the current study was to identify miRs that can predict local control after breast conserving therapy (BCT) in early stage breast cancer.

Results: Clinical data of 46 early stage breast cancer patients with local relapse after BCT were selected from the institutional database. These patients were matched to 101 control patients showing identical clinical features but without local relapse. The study was conducted in two steps. (1) In the pilot study, 32 patients (16 relapses versus 16 controls) were screened for the most de-regulated microRNAs (= candidate microRNAs) in a panel of 1250 miRs by microarray technology. Eight miRs were found to be significantly de-regulated. (2) In the validation study, the candidate microRNAs were analyzed in an independent cohort of 115 patients (30 relapses versus 85 controls) with reverse transcription quantitative polymerase chain reaction (RT-qPCR). From these eight candidates, hsa-miR-375 could be validated. Its median fold change was 2.28 (Mann-Whitney U test, corrected p value = 0.008). In the log-rank analysis, high expression levels of hsa-miR-375 correlated with a significantly higher risk of local relapse (p = 0.003). In a multivariate analysis (forward stepwise regression) including established predictors and prognosticators, hsa-miR-375 was the only variable that was able to distinguish the statistical significance between relapse and control groups (raw p value = 0.000195 HR = 0.76, 95 % CI 0.66-0.88; corrected p value = 0.005).

Conclusions: Hsa-miR-375 predicts local control in patient with early stage breast cancer, especially in estrogen receptor α (ER-α)-positive patients. It can therefore serve as an additional molecular marker for treatment choice independently from known predictors and prognosticators. Validation in larger prospective studies is warranted.

Citing Articles

MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype.

Tariq M, Richard V, Kerin M Biomedicines. 2023; 11(11).

PMID: 38002007 PMC: 10669494. DOI: 10.3390/biomedicines11113007.

The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies.

Yang M, Zhang Y, Li M, Liu X, Darvishi M Cancer Cell Int. 2023; 23(1):24.

PMID: 36765409 PMC: 9912632. DOI: 10.1186/s12935-022-02837-y.

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer.

Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D Cancers (Basel). 2022; 14(12).

PMID: 35740618 PMC: 9221286. DOI: 10.3390/cancers14122952.

Differential mRNA Expression Profiling Reveals the Role of MiR-375 in Inflammation of Bovine Mammary Epithelial Cells.

Li Y, Hu Q, Luoreng Z, Yang J, Wang X, Ma Y Animals (Basel). 2022; 12(11).

PMID: 35681895 PMC: 9179474. DOI: 10.3390/ani12111431.

miRNAs Contained in Extracellular Vesicles Cargo Contribute to the Progression of Idiopathic Pulmonary Fibrosis: An In Vitro Aproach.

Santos-Alvarez J, Velazquez-Enriquez J, Garcia-Carrillo R, Rodriguez-Beas C, Ramirez-Hernandez A, Reyes-Jimenez E Cells. 2022; 11(7).

PMID: 35406675 PMC: 8997737. DOI: 10.3390/cells11071112.

References

Kovalchuk O, Tryndyak V, Montgomery B, Boyko A, Kutanzi K, Zemp F . Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle. 2007; 6(16):2010-8. DOI: 10.4161/cc.6.16.4549. View

Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J . Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol. 2011; 22(10):2257-66. DOI: 10.1093/annonc/mdq758. View

Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L . Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002; 94(15):1143-50. DOI: 10.1093/jnci/94.15.1143. View

Vaidyanathan G, Cismowski M, Wang G, Vincent T, Brown K, Lanier S . The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene. 2004; 23(34):5858-63. DOI: 10.1038/sj.onc.1207774. View

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

Selth L, Townley S, Gillis J, Ochnik A, Murti K, Macfarlane R . Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2011; 131(3):652-61. DOI: 10.1002/ijc.26405. View

Giricz O, Reynolds P, Ramnauth A, Liu C, Wang T, Stead L . Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol. 2011; 226(1):108-19. DOI: 10.1002/path.2978. View

Sautter-Bihl M, Sedlmayer F, Budach W, Dunst J, Feyer P, Fietkau R . One life saved by four prevented recurrences? Update of the Early Breast Cancer Trialists confirms: postoperative radiotherapy improves survival after breast conserving surgery. Strahlenther Onkol. 2012; 188(6):461-3. DOI: 10.1007/s00066-012-0092-5. View

Lowery A, Miller N, Devaney A, McNeill R, Davoren P, Lemetre C . MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11(3):R27. PMC: 2716495. DOI: 10.1186/bcr2257. View

10.

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

11.

Mattie M, Benz C, Bowers J, Sensinger K, Wong L, Scott G . Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5:24. PMC: 1563474. DOI: 10.1186/1476-4598-5-24. View

12.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

13.

Smith T, Lee D, Turner B, Carter D, Haffty B . True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000; 48(5):1281-9. DOI: 10.1016/s0360-3016(00)01378-x. View

14.

Lazaridis G, Lambaki S, Karayannopoulou G, Eleftheraki A, Papaspirou I, Bobos M . Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlenther Onkol. 2014; 190(7):636-8, 640-5. DOI: 10.1007/s00066-014-0620-6. View

15.

Sperveslage J, Hoffmeister M, Henopp T, Kloppel G, Sipos B . Establishment of robust controls for the normalization of miRNA expression in neuroendocrine tumors of the ileum and pancreas. Endocrine. 2014; 46(2):226-30. DOI: 10.1007/s12020-014-0202-5. View

16.

Jonsdottir K, Janssen S, Da Rosa F, Gudlaugsson E, Skaland I, Baak J . Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One. 2012; 7(11):e48692. PMC: 3492447. DOI: 10.1371/journal.pone.0048692. View

17.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

18.

Witkos T, Koscianska E, Krzyzosiak W . Practical Aspects of microRNA Target Prediction. Curr Mol Med. 2011; 11(2):93-109. PMC: 3182075. DOI: 10.2174/156652411794859250. View

19.

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

20.

Bhat-Nakshatri P, Wang G, Collins N, Thomson M, Geistlinger T, Carroll J . Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009; 37(14):4850-61. PMC: 2724297. DOI: 10.1093/nar/gkp500. View